All In Biotech

Drug Trial Radar · NCT03762759

Fluciclovine F18 or Ga68-PSMA PET/CT to Enhance Prostate Cancer Outcomes

Advanced PET-CT Directed Post-Prostatectomy Radiotherapy to Enhance Prostate Cancer Outcomes

Last checked: Nov 20, 2026Latest source record: Sep 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registryPivotal-lookingRandomized with 140 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

140

Actual

Start

May 10, 2019

Primary completion

May 19, 2025

Study completion May 19, 2030

Sponsor

Lead sponsor
Emory UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Telix Pharmaceuticals (Innovations) Pty Limited; National Cancer Institute (NCI); National Institutes of Health (NIH)
First posted
Dec 4, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase II trial studies how well a positron emission tomography (PET)/computed tomography (CT) scan using fluciclovine F18 compared with a PET/CT scan with 68Ga-PSMA works in planning radiation treatments and enhancing outcomes in patients with prostate adenocarcinoma. Fluciclovine F18 and 68Ga-PSMA are types of tracers, called radiotracers, that are injected and can accumulate in tumor cells to develop images of them during a PET/CT scan. It is not yet known whether giving fluciclovine F18 or 68Ga-PSMA may work better in planning radiation treatments and enhancing outcomes in patients with prostate adenocarcinoma.

Conditions

  • Prostate Adenocarcinoma

Interventions

  • Computed TomographyProcedure

    Undergo PET/CT

  • Fluciclovine F18Drug

    Given IV

  • Gallium Ga68-labeled PSMA-11Radiation

    Given IV

  • Positron Emission TomographyProcedure

    Undergo PET/CT

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Disease-Free at 2 YearsTime frame: Up to 2 years after study start

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Grady Health System

    Atlanta, Georgia

  • Emory University Hospital/Winship Cancer Institute

    Atlanta, Georgia

  • Emory Saint Joseph's Hospital

    Atlanta, Georgia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.